js212
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 11, 2025 (NCT06888830)
Timeline
Indications
Studied for
Mechanism of action
ERBB3 inhibitor
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07309276 | Phase 2 | Dec 30, 2025 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT06888830 | Phase 1/Phase 2 (Phase 2) | Apr 11, 2025 | Shanghai Junshi Bioscience Co.,Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Junshi Bioscience Co.,Ltd. | For profit | 2 | 2 | 1 | 2025 |
1 organizations
Page 1 / 1